Price$0.46-0.36 (-43.50%)
2026-01-272026-04-30
News · 26 weeks64+167%
2025-11-022026-04-26
Mix2690d
- SEC Filings14(54%)
- Insider6(23%)
- Other3(12%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- SECAccuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- PRAccuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), c
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Accuray IncorporatedSCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)
- INSIDERSEC Form 3 filed by new insider Tcw Group Inc3 - ACCURAY INC (0001138723) (Issuer)
- INSIDERSEC Form 3 filed by new insider Miele Paul Michael3 - ACCURAY INC (0001138723) (Issuer)
- SECAccuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- PRAccuray Appoints Paul Miele as Senior Vice President and Chief Commercial OfficerMADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform
- INSIDERSEC Form 4 filed by Chalke Sandeep4 - ACCURAY INC (0001138723) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Accuray IncorporatedSCHEDULE 13G/A - ACCURAY INC (0001138723) (Subject)
- SECAccuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- INSIDERSVP, Chief Operations Officer Peralta Leonel converted options into 83,723 shares and covered exercise/tax liability with 28,969 shares (SEC Form 4)4 - ACCURAY INC (0001138723) (Issuer)
- SECSEC Form EFFECT filed by Accuray IncorporatedEFFECT - ACCURAY INC (0001138723) (Filer)
- SECSEC Form 424B3 filed by Accuray Incorporated424B3 - ACCURAY INC (0001138723) (Filer)
- INSIDERDirector Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)4 - ACCURAY INC (0001138723) (Issuer)
- INSIDERDirector Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)4 - ACCURAY INC (0001138723) (Issuer)
- SECSEC Form S-3 filed by Accuray IncorporatedS-3 - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECSEC Form 10-Q filed by Accuray Incorporated10-Q - ACCURAY INC (0001138723) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by Accuray Incorporated10-Q/A - ACCURAY INC (0001138723) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Accuray Incorporated10-K/A - ACCURAY INC (0001138723) (Filer)
- SECSEC Form NT 10-Q filed by Accuray IncorporatedNT 10-Q - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
ARAY FAQ
7 questionsWhat does Accuray Incorporated do?
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of...Where does ARAY stock trade?
Accuray Incorporated (ARAY) is listed on NASDAQ.What sector and industry is ARAY in?
Accuray Incorporated operates in the Health Care sector, Medical/Dental Instruments industry.When did Accuray Incorporated go public?
Accuray Incorporated (ARAY) completed its IPO in 2007.What are analysts saying about ARAY?
Accuray Incorporated has had 3 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $900.00 price target on 2024-02-13. Recent price targets range from $750.00 to $900.00.What companies are similar to ARAY?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare ARAY side-by-side with any of them on Quantisnow.How can I track ARAY on Quantisnow?
Quantisnow aggregates Accuray Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARAY to receive live email and push alerts on every new disclosure.